The Bull Rankings scorecard — our quality-growth score is 43.1 / 100, built from three pillars scored 0–100: Quality 47, Growth 85, Value 20 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 26% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Medline’s growth engine is intact, but the price already demands 26% free-cash-flow growth next year, slowing only gradually to 3% a year by year ten. In the quarter ended 2025-12-31, revenue grew 11.5% year over year while free cash flow clocked in at $1.3 billion, yet the stock trades at 44.1 times trailing earnings. Our model gives the business a Quality-growth score of 43.1/100, split between Quality (47), Growth (85), and Value (20), making the weakest pillar plain: value. The market has priced in a reverse-DCF scenario that requires free-cash-flow growth of roughly 26% next year, slowing to 3% a year by year ten, a starting rate that towers over the 11.5% revenue expansion reported for the period. Either the growth accelerates or the multiple compresses; there is no third option.
What the business actually is
Medline sells the nuts and bolts of care delivery: surgical solutions, front-line care products, and laboratory diagnostics. The front-line care line alone covers wound care, exam gloves, skin care, incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, and patient plastics. It serves hospitals, surgery centers, physician offices, post-acute facilities, and nursing homes across the U.S. and internationally, split between the Medline Brand segment and the Supply Chain Solutions segment. The Brand segment manufactures and procures the products; the Supply Chain Solutions segment moves them. The Brand segment is the growth engine, riding secular demand for med-surg consumables and equipment that show up in every site of care.
Why it can (or can't) keep compounding
The durability story hinges on the moat around supply-chain density and product breadth. Medline’s return on equity sits at 10.1% in the latest quarter, respectable rather than exceptional. The company’s two-segment model—own-brand products plus logistics—creates switching costs: once a hospital integrates Medline’s gloves, wound care kits, and cleaning supplies into its daily workflow, swapping vendors means retraining staff, reconfiguring storage, and revalidating infection-control protocols. Competitors can match any single product line, but replicating the full catalog with the same on-demand delivery footprint takes years and a vast inventory.
Our model’s strongest pillar is Growth at 85, driven by the 11.5% revenue growth in the most recent quarter. The short track record flag, however, cautions that the growth spurt may not yet be battle-tested through a full cycle. If the hospital capital cycle softens or private-label pressure intensifies, the growth could downshift without warning.
The valuation question
The stock’s 44.1 P/E and implied 26% annual free-cash-flow growth (in year one, slowing to 3% a year by year ten) reveal a market that has assumed perfection. Actual revenue growth in the quarter ended 2025-12-31 was 11.5%, less than half the reverse-DCF hurdle. The PEG ratio of 12.6 points the same way: the multiple is very high for the earnings growth analysts expect. Either Medline’s free-cash-flow conversion accelerates materially above its current level or the multiple contracts; there is no middle ground priced in.
The bear case
The weakest pillar is Value at 20, and the profit margin adds to the concern: at 4.1%, Medline’s earnings power is thin for a $47.5 billion franchise. Gross margins are exposed to commodity input costs, while the heavy lifting of supply-chain investment keeps capital returns modest. If the 4.1% margin slips another 50 basis points, the entire growth narrative starts to look like a bet on volume rather than pricing power.
What would change our mind
Two falsifiable conditions would flip the thesis. First, if the revenue growth rate sustained above 15% while the profit margin held at or above 4.1%, the multiple would look less stretched. Second, if free cash flow grew well beyond $1.3 billion without resorting to leverage, the $47.5 billion valuation would start to look reasonable. Watch the next quarterly update: any deceleration below 9% growth or a margin dip below 4.1% would confirm the bear case.